CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho, Sang Youb Han
Kidney Res Clin Pract. 2017;36(3):274-281.   Published online September 30, 2017
DOI: https://doi.org/10.23876/j.krcp.2017.36.3.274

Excel Download

102 Renoprotective Effects of Febuxostat and Allopurinol in patients with Hyperuricemia and Chronic Kidney Disease: A Meta-Analysis
American Journal of Kidney Diseases. 2020;75(4):565   Crossref logo
Link1 Link2

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
Kidney Research and Clinical Practice. 2017;36(3):274-281   Crossref logo
Link1 Link2

SO012RENOPROTECTIVE EFFECTS OF FEBUXOSTAT AND ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND CHRONIC KIDNEY DISEASES: A META-ANALYSIS
Nephrology Dialysis Transplantation. 2020;35(Supplement_3):   Crossref logo
Link1 Link2

Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout
Yearbook of Pediatrics. 2007;2007:501-503   Crossref logo
Link1 Link2

P276 A meta-analysis on the association of febuxostat compared to allopurinol on blood pressure and major adverse cardiac events (MACE) among adult patients with hyperuricemia
European Heart Journal. 2020;41(Supplement_1):   Crossref logo
Link1 Link2

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
Clinical Cardiology. 2022;   Crossref logo
Link1 Link2 Link3

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
Clinical Cardiology. 2021;   Crossref logo
Link1 Link2 Link3

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
Clinical Cardiology. 2022;   Crossref logo
Link1 Link2 Link3

Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review
Clinical Rheumatology. 2020;39(11):3287-3294   Crossref logo
Link1 Link2 Link3

The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia – A systematic review and meta-analysis
Nutrition, Metabolism and Cardiovascular Diseases. 2019;29(10):1011-1022   Crossref logo
Link1 Link2